Literature DB >> 22234167

The unique profile of cord blood natural killer cells balances incomplete maturation and effective killing function upon activation.

Martha Luevano1, Mehri Daryouzeh, Rehab Alnabhan, Sergio Querol, Salim Khakoo, Alejandro Madrigal, Aurore Saudemont.   

Abstract

Cord blood (CB) is increasingly used as a source of stem cells for hematopoietic stem cell transplantation, and natural killer (NK) cells may be the effectors of the antileukemic response observed after CB transplantation. Here, we analyzed the phenotype and functions of CB NK cell subsets. We determined that the percentage of NK cells was higher in CB compared with peripheral blood (PB). Furthermore, there was a higher percentage of the CD56(bright) subset in CB. CB NK cells reached a late stage of differentiation, but exhibited higher expression of NKG2A and expressed fewer killer-cell immunoglobulin-like receptors, suggesting an incomplete maturation. CB NK cells highly expressed CXCR4, but did not express L-selectin, highlighting unique homing properties of CB NK cells. CB NK cells proliferated in response to interleukin-2 and degranulated in response to stimulation with tumor cells, but failed to lyse K562 cells in (51)Cr-release assay. CB NK cells exhibited a lower interferon-γ production in comparison with PB NK cells. Culture with IL-2 increased CB NK cell functions. Our study sheds light on CB NK cell properties and highlights the potential of CB as a source of NK cells for immunotherapy. Copyright Â
© 2012 American Society for Histocompatibility and Immunogenetics. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22234167     DOI: 10.1016/j.humimm.2011.12.015

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  53 in total

1.  Neutrophilic myeloid-derived suppressor cells in cord blood modulate innate and adaptive immune responses.

Authors:  N Rieber; C Gille; N Köstlin; I Schäfer; B Spring; M Ost; H Spieles; H A Kugel; M Pfeiffer; V Heininger; M Alkhaled; A Hector; L Mays; M Kormann; S Zundel; J Fuchs; R Handgretinger; C F Poets; D Hartl
Journal:  Clin Exp Immunol       Date:  2013-10       Impact factor: 4.330

2.  Zoledronate increases enrichment, activation and expansion of natural killer cells from umbilical cord blood.

Authors:  Zhijie Ma; Yunhong Wang; Huiyan Kang; Xiaoyun Wu
Journal:  Hum Cell       Date:  2018-06-13       Impact factor: 4.174

3.  Maternal obesity is associated with phenotypic alterations in fetal immune cells by single-cell mass cytometry.

Authors:  Elizabeth Ann L Enninga; Jin Sung Jang; Benjamin Hur; Erica L Johnson; Myra J Wick; Jaeyun Sung; Rana Chakraborty
Journal:  Am J Reprod Immunol       Date:  2020-11-04       Impact factor: 3.886

4.  A novel method to expand large numbers of CD56(+) natural killer cells from a minute fraction of selectively accessed cryopreserved cord blood for immunotherapy after transplantation.

Authors:  Sumithira Vasu; Maria Berg; Jan Davidson-Moncada; Xin Tian; Herb Cullis; Richard W Childs
Journal:  Cytotherapy       Date:  2015-11       Impact factor: 5.414

5.  Efficacy of third-party chimeric antigen receptor modified peripheral blood natural killer cells for adoptive cell therapy of B-cell precursor acute lymphoblastic leukemia.

Authors:  C Quintarelli; S Sivori; S Caruso; S Carlomagno; L Moretta; F Locatelli; M Falco; I Boffa; D Orlando; M Guercio; Z Abbaszadeh; M Sinibaldi; S Di Cecca; A Camera; B Cembrola; A Pitisci; M Andreani; L Vinti; S Gattari; F Del Bufalo; M Algeri; G Li Pira; A Moseley; B De Angelis
Journal:  Leukemia       Date:  2019-11-19       Impact factor: 11.528

6.  Eomesodermin and T-bet mark developmentally distinct human natural killer cells.

Authors:  Amélie Collins; Nyanza Rothman; Kang Liu; Steven L Reiner
Journal:  JCI Insight       Date:  2017-03-09

7.  Enhanced cytotoxic function of natural killer and CD3+CD56+ cells in cord blood after culture.

Authors:  Suzanne L Tomchuck; Wing H Leung; Mari H Dallas
Journal:  Biol Blood Marrow Transplant       Date:  2014-10-18       Impact factor: 5.742

Review 8.  Exploring the NK cell platform for cancer immunotherapy.

Authors:  Jacob A Myers; Jeffrey S Miller
Journal:  Nat Rev Clin Oncol       Date:  2020-09-15       Impact factor: 66.675

Review 9.  Post-autologous transplant maintenance therapies in lymphoid malignancies: are we there yet?

Authors:  N Epperla; T S Fenske; H M Lazarus; M Hamadani
Journal:  Bone Marrow Transplant       Date:  2015-08-17       Impact factor: 5.483

Review 10.  NK Cell Adoptive Immunotherapy of Cancer: Evaluating Recognition Strategies and Overcoming Limitations.

Authors:  Carlos E Sanchez; Ehsan P Dowlati; Ashley E Geiger; Kajal Chaudhry; Matthew A Tovar; Catherine M Bollard; Conrad Russell Y Cruz
Journal:  Transplant Cell Ther       Date:  2020-09-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.